Brunswick Exploration Unpacks 302-Metre Lithium Hit as Retail Traders Battle Over ValuationOct 15 Lux Metals Ignites James Bay with 17.57 g/t Gold Intercept Over 19.5 MetresOct 14 Mining Industry Veteran Michael Williams Appointed Executive Chairman of Canadian Uraniumlive
SPONSORED
CannabisHealth Care

Half of all multiple sclerosis patients now use cannabis

For people diagnosed with MS, cannabis has the promise of symptom relief.

•• 3 Min
Half of all multiple sclerosis patients now use cannabis

According to a study by researchers at the University of Michigan, more than 40% of patients with multiple sclerosis have used cannabis or cannabinoid products in the past year. The study, titled "Cannabinoid Use Among Americans With MS: Current Trends and Knowledge Gaps," was recently published in the Multiple Sclerosis Journal - Experimental, Translational and Clinical.

To conduct the research, the University of Michigan researchers collected data from a statewide sample of more than 1,000 patients with multiple sclerosis. The study found that 42% of respondents said they had used cannabis or cannabinoid-based therapies such as cannabidiol (CBD) in the past year, a rate of use almost double that, according to the National Organization for the Reform of Marijuana Laws (NORML) is like the national average. "These national survey data underscore the increasing prevalence of cannabinoid use among Americans with MS and the continued perception of the benefits for several chronic symptoms among users," the researchers wrote.

Of those surveyed who have used cannabis or cannabinoid products, 90% said their cannabis use was medicinal in nature. The researchers found that many patients with MS have chronic symptoms for which there are not enough quality treatment options. More than half of all patients suffer from chronic pain, which can also affect sleep. At least 60% have insomnia, which can lead to fatigue and other chronic symptoms. The lack of effective treatment options is causing many MS patients to seek alternative therapies, including cannabis and cannabinoid products like CBD.

However, little information is available on the proper use and dosage of cannabis required for effective treatment of MS, leading the study's authors to request more research on the subject. "Many Americans with MS use cannabinoids, and especially CBD-predominant products, to manage a wide range of symptoms on their own," they wrote. "These results highlight the critical gaps between community use and clinical care, and illustrate an immediate need for prospective, mechanistic studies focusing on the effects of cannabinoids on chronic MS symptoms, as well as the interactions between MS symptoms ".

Cannabis is effective for a range of MS symptoms The patients who used cannabis to treat their MS found that cannabis was most effective at improving sleep and reducing tremors, as well as relieving nausea and anxiety. The researchers found that most patients who chose cannabis to treat their MS wanted more information about cannabis use, but did not get such advice from their healthcare provider. "Interestingly, the overwhelming majority of respondents expressed a desire to receive more advice on cannabis use from health care providers, but less than 1% received information from their provider about the type of cannabinoid product they were consuming," the authors found. The researchers concluded that the popularity of cannabis use among MS patients and the perceived range of benefits of THC and CBD highlighted the need for more research and "personalized, evidence-based guidelines on cannabinoid use".

"Our results also show a growing discrepancy between cannabinoid use and clinical guidelines for use, underscoring the growing need to determine whether and how cannabinoids can be used more effectively to treat some of the most debilitating MS symptoms for which it is currently there are no high quality interventions, as well as the need to encourage more open educational discussions between providers and patients in order to optimize cannabinoid use, ”they wrote.

CannabisHealthcare

More from Cannabis

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.